$10.09
5.61% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US2928121043
Symbol
ENFN

Enfusion Stock price

$10.09
+0.07 0.70% 1M
+1.50 17.46% 6M
+0.39 4.02% YTD
+0.31 3.17% 1Y
-9.51 48.52% 3Y
-9.72 49.07% 5Y
-9.72 49.07% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.60 5.61%
ISIN
US2928121043
Symbol
ENFN

Key metrics

Market capitalization $952.21m
Enterprise Value $951.29m
P/E (TTM) P/E ratio 385.11
EV/FCF (TTM) EV/FCF 47.76
EV/Sales (TTM) EV/Sales 4.87
P/S ratio (TTM) P/S ratio 4.88
P/B ratio (TTM) P/B ratio 13.46
Revenue growth (TTM) Revenue growth 15.78%
Revenue (TTM) Revenue $195.16m
EBIT (operating result TTM) EBIT $6.71m
Free Cash Flow (TTM) Free Cash Flow $19.92m
Cash position $48.30m
EPS (TTM) EPS $0.03
P/E forward 173.59
P/S forward 4.69
EV/Sales forward 4.68
Short interest 1.78%
Show more

Is Enfusion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Enfusion Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Enfusion forecast:

3x Buy
30%
3x Hold
30%
4x Sell
40%

Analyst Opinions

10 Analysts have issued a Enfusion forecast:

Buy
30%
Hold
30%
Sell
40%

Financial data from Enfusion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
195 195
16% 16%
100%
- Direct Costs 64 64
16% 16%
33%
131 131
16% 16%
67%
- Selling and Administrative Expenses 88 88
26% 26%
45%
- Research and Development Expense 26 26
37% 37%
13%
17 17
30% 30%
9%
- Depreciation and Amortization 11 11
22% 22%
5%
EBIT (Operating Income) EBIT 6.71 6.71
40% 40%
3%
Net Profit 3.34 3.34
43% 43%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Enfusion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enfusion Stock News

Positive
Seeking Alpha
5 days ago
I maintain a buy rating for ENFN, anticipating revenue growth to exceed 20% due to improving macro conditions and solid execution. The macro environment has shown signs of turnaround, with rate cuts and reduced election uncertainty, boosting demand sentiment. ENFN's strong execution is evident in stable front book revenue growth, customer additions, and successful upmarket penetration.
Neutral
Business Wire
13 days ago
NEW YORK & LONDON--(BUSINESS WIRE)-- #DigitalTransformation--Orbus Software announces strategic growth investment from FTV Capital and SilverTree Equity.
Neutral
Business Wire
about one month ago
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion's Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: Wells Fargo 8th Annual TMT Summit on Tuesday, December 3, ...
More Enfusion News

Company Profile

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded in 2006 and is headquartered in Chicago, IL.

Head office United States
CEO Oleg Movchan
Employees 1,102
Founded 2006
Website enfusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today